Loading
Most genomic and liquid biopsy tests are reimbursed on analytical validity and association with outcome, not on proof that they improve care. Paying for new oncology biomarker tests only inside registries or randomised studies, as Medicare did for PET, would sort the useful from the useless.
Most genomic and liquid biopsy tests are reimbursed on analytical validity and association with outcome, not on demonstrated clinical utility. Coverage with evidence development, used by Medicare for PET and for some genomic tests, ties payment to enrolment in a registry or randomised study. Applying it systematically to new oncology biomarker tests would generate utility evidence at the scale of routine practice and remove payment for tests that fail.
Shares Examination of Low ERBB2 Protein Expression in Breast Cancer Tissue, Companion diagnostic, Biomarkers are not validated or standardised.
Shares Examination of Low ERBB2 Protein Expression in Breast Cancer Tissue, Companion diagnostic, Biomarkers are not validated or standardised.
Shares Examination of Low ERBB2 Protein Expression in Breast Cancer Tissue, Companion diagnostic, Biomarkers are not validated or standardised.
Shares Payers cover off-label combinations only inside registry-randomised trials, Real-world evidence.
Shares Examination of Low ERBB2 Protein Expression in Breast Cancer Tissue, Companion diagnostic, Biomarkers are not validated or standardised.
Shares Companion diagnostic, Biomarkers are not validated or standardised.
Shares Examination of Low ERBB2 Protein Expression in Breast Cancer Tissue, Companion diagnostic, Biomarkers are not validated or standardised.
Shares Examination of Low ERBB2 Protein Expression in Breast Cancer Tissue, Biomarkers are not validated or standardised.